---
title: "Heartburn and digestive brands in the United States: Which are searched most?"
description: "Compare the antacid, reflux and upset stomach brands Americans buy. Share of Search among Pepto-Bismol, Pepcid, Prilosec OTC, Tums, Nexium and Gaviscon, the heartburn and digestive brands Brandwave compares in the United States, using the same methodology, market, and reporting period. Branded searches tell you how often people look for a brand by name or related terms. Comparing these searches across competitors helps you see how popular each brand is over time."
canonical: "https://gobrandwave.com/demand/us/categories/us-heartburn-and-digestive-brands"
publisher: "Brandwave"
---

# Heartburn and digestive brands in the United States: Which are searched most?

Compare the antacid, reflux and upset stomach brands Americans buy. Share of Search among Pepto-Bismol, Pepcid, Prilosec OTC, Tums, Nexium and Gaviscon, the heartburn and digestive brands Brandwave compares in the United States, using the same methodology, market, and reporting period. Branded searches tell you how often people look for a brand by name or related terms. Comparing these searches across competitors helps you see how popular each brand is over time.

## Key facts

- **Competitive set**: Heartburn and digestive brands
- **Market**: United States
- **Brands compared**: 6
- **Month measured**: Sep 2026
- **Highest Share of Search**: Pepto-Bismol, 31.1%

## Which brand is most popular in search among heartburn and digestive brands in the United States?

- In September 2026, Pepto-Bismol was the most searched among heartburn and digestive brands in the United States, with an estimated 301K branded searches, 31.1% of all searches for the six we track.
- Pepcid is in 2nd place, 5.7 percentage points behind at 25.4%.
- Across the 12 months ending September 2026, Pepcid’s share of searches among heartburn and digestive brands in the United States increased from 21.1% to 25.4%.
- Across the 12 months ending September 2026, Prilosec OTC’s share of searches among heartburn and digestive brands in the United States decreased from 17.3% to 13.9%.
- Across the 12 months ending September 2026, Pepto-Bismol’s share of searches among heartburn and digestive brands in the United States peaked at 33.5% in February 2026 and was lowest at 26.9% in June 2026.
- Across the 12 months ending September 2026, Pepcid’s share of searches among heartburn and digestive brands in the United States peaked at 26.9% in June 2026 and was lowest at 21.1% in October 2025.
- Across the 12 months ending September 2026, Prilosec OTC’s share of searches among heartburn and digestive brands in the United States peaked at 17.3% in October 2025 and was lowest at 13.9% in April 2026.
- Across the 12 months ending September 2026, Tums’ share of searches among heartburn and digestive brands in the United States peaked at 15.8% in November 2025 and was lowest at 12.2% in February 2026.
- Across the 12 months ending September 2026, Nexium’s share of searches among heartburn and digestive brands in the United States peaked at 10.6% in November 2025 and was lowest at 7.8% in July 2026.
- Across the 12 months ending September 2026, Gaviscon’s share of searches among heartburn and digestive brands in the United States peaked at 7.9% in December 2025 and was lowest at 5.8% in November 2025.
- Across the 12 months ending September 2026, Pepto-Bismol, Tums, Nexium and Gaviscon held steady: their share of searches among heartburn and digestive brands in the United States each moved less than 0.5 percentage points.

## Top heartburn and digestive brands in ChatGPT and Google AI Overviews

In Brandwave's three ChatGPT questions and two Google AI Overviews, Tums appeared every time. Tums was recommended most often, coming first in all three answers that gave a list. Pepcid was second, and Prilosec OTC was third.

Brands get a higher AI rank if they are mentioned earlier in the answers that list options.

| Brand | AI rank | ChatGPT answers that named it | Google AI Overviews that named it | All answers that named it |
| --- | --- | --- | --- | --- |
| Tums | 1st | 3 of 3 | 2 of 2 | 5 of 5 |
| Pepcid | 2nd | 2 of 3 | 1 of 2 | 3 of 5 |
| Prilosec OTC | 3rd | 2 of 3 | 1 of 2 | 3 of 5 |
| Pepto-Bismol | 4th | 1 of 3 | 1 of 2 | 2 of 5 |
| Gaviscon | 5th | 1 of 3 | 0 of 2 | 1 of 5 |
| Nexium | 6th | 0 of 3 | 1 of 2 | 1 of 5 |

## Every AI answer about heartburn and digestive brands

- Asked ChatGPT "What's the best medicine for heartburn?": 1. Tums, 2. Pepcid, 3. Prilosec OTC
- Asked ChatGPT "What's the best antacid?": 1. Tums, 2. Gaviscon, 3. Pepcid, 4. Prilosec OTC
- Asked ChatGPT "What should I take for an upset stomach?": 1. Pepto-Bismol, 2. Tums
- Searched Google, AI Overview "heartburn medicine": 1. Tums, 2. Pepto-Bismol, 3. Pepcid, 4. Prilosec OTC, 5. Nexium
- Searched Google, AI Overview "antacid": 1. Tums

Brands are listed in the order each answer named them. The answers were collected in United States on October 27, 2026.

## Compare search popularity between leading brands

- [Pepto-Bismol vs Pepcid: compare search popularity](/demand/us/compare/pepcid-vs-pepto-bismol): 31.1% against 25.4% Share of Search.
- [Pepto-Bismol vs Prilosec OTC: compare search popularity](/demand/us/compare/pepto-bismol-vs-prilosec): 31.1% against 13.9% Share of Search.
- [Pepto-Bismol vs Tums: compare search popularity](/demand/us/compare/pepto-bismol-vs-tums): 31.1% against 13.9% Share of Search.
- [Pepto-Bismol vs Nexium: compare search popularity](/demand/us/compare/nexium-vs-pepto-bismol): 31.1% against 9.3% Share of Search.
- [Pepcid vs Prilosec OTC: compare search popularity](/demand/us/compare/pepcid-vs-prilosec): 25.4% against 13.9% Share of Search.
- [Pepcid vs Tums: compare search popularity](/demand/us/compare/pepcid-vs-tums): 25.4% against 13.9% Share of Search.
- [Pepcid vs Nexium: compare search popularity](/demand/us/compare/nexium-vs-pepcid): 25.4% against 9.3% Share of Search.
- [Prilosec OTC vs Tums: compare search popularity](/demand/us/compare/prilosec-vs-tums): 13.9% Share of Search each.
- [Prilosec OTC vs Nexium: compare search popularity](/demand/us/compare/nexium-vs-prilosec): 13.9% against 9.3% Share of Search.
- [Tums vs Nexium: compare search popularity](/demand/us/compare/nexium-vs-tums): 13.9% against 9.3% Share of Search.

## How did search popularity change for United States heartburn and digestive brands in September 2026?

- Estimated monthly branded searches for Pepcid in the United States rose 22.4% over 12 measured months, from 201K to 246K in September 2026.
- Estimated monthly branded searches for Prilosec OTC in the United States fell 18.2% over 12 measured months, from 165K to 135K in September 2026.

## Share of Search ranking

| Rank | Brand | Share of Search | Estimated monthly branded searches | Change vs prior month | Owned by |
| --- | --- | --- | --- | --- | --- |
| 1 | Pepto-Bismol | 31.1% | 301K | 0.0% | Pepto-Bismol |
| 2 | Pepcid | 25.4% | 246K | 0.0% | Pepcid |
| 3 | Prilosec OTC | 13.9% | 135K | 0.0% | Prilosec OTC |
| 4 | Tums | 13.9% | 135K | 0.0% | Tums |
| 5 | Nexium | 9.3% | 90.5K | 0.0% | Nexium |
| 6 | Gaviscon | 6.3% | 60.5K | 0.0% | Reckitt |

## Historical estimated branded-search demand

| Month | Brand | Estimated monthly branded searches | Share of Search | Rank |
| --- | --- | --- | --- | --- |
| Oct 2025 | Pepto-Bismol | 301K | 31.6% | 1 |
| Oct 2025 | Pepcid | 201K | 21.1% | 2 |
| Oct 2025 | Prilosec OTC | 165K | 17.3% | 3 |
| Oct 2025 | Tums | 135K | 14.2% | 4 |
| Oct 2025 | Nexium | 90.5K | 9.5% | 5 |
| Oct 2025 | Gaviscon | 60.5K | 6.3% | 6 |
| Nov 2025 | Pepto-Bismol | 246K | 28.7% | 1 |
| Nov 2025 | Pepcid | 201K | 23.5% | 2 |
| Nov 2025 | Prilosec OTC | 135K | 15.8% | 3 |
| Nov 2025 | Tums | 135K | 15.8% | 4 |
| Nov 2025 | Nexium | 90.5K | 10.6% | 5 |
| Nov 2025 | Gaviscon | 49.5K | 5.8% | 6 |
| Dec 2025 | Pepto-Bismol | 301K | 32.1% | 1 |
| Dec 2025 | Pepcid | 201K | 21.5% | 2 |
| Dec 2025 | Prilosec OTC | 135K | 14.4% | 3 |
| Dec 2025 | Tums | 135K | 14.4% | 4 |
| Dec 2025 | Nexium | 90.5K | 9.7% | 5 |
| Dec 2025 | Gaviscon | 74K | 7.9% | 6 |
| Jan 2026 | Pepto-Bismol | 301K | 31.6% | 1 |
| Jan 2026 | Pepcid | 201K | 21.1% | 2 |
| Jan 2026 | Prilosec OTC | 165K | 17.3% | 3 |
| Jan 2026 | Tums | 135K | 14.2% | 4 |
| Jan 2026 | Nexium | 90.5K | 9.5% | 5 |
| Jan 2026 | Gaviscon | 60.5K | 6.3% | 6 |
| Feb 2026 | Pepto-Bismol | 301K | 33.5% | 1 |
| Feb 2026 | Pepcid | 201K | 22.4% | 2 |
| Feb 2026 | Prilosec OTC | 135K | 15% | 3 |
| Feb 2026 | Tums | 110K | 12.2% | 4 |
| Feb 2026 | Nexium | 90.5K | 10.1% | 5 |
| Feb 2026 | Gaviscon | 60.5K | 6.7% | 6 |
| Mar 2026 | Pepto-Bismol | 301K | 30.2% | 1 |
| Mar 2026 | Pepcid | 246K | 24.6% | 2 |
| Mar 2026 | Prilosec OTC | 165K | 16.5% | 3 |
| Mar 2026 | Tums | 135K | 13.5% | 4 |
| Mar 2026 | Nexium | 90.5K | 9.1% | 5 |
| Mar 2026 | Gaviscon | 60.5K | 6.1% | 6 |
| Apr 2026 | Pepto-Bismol | 301K | 31.1% | 1 |
| Apr 2026 | Pepcid | 246K | 25.4% | 2 |
| Apr 2026 | Prilosec OTC | 135K | 13.9% | 3 |
| Apr 2026 | Tums | 135K | 13.9% | 4 |
| Apr 2026 | Nexium | 90.5K | 9.3% | 5 |
| Apr 2026 | Gaviscon | 60.5K | 6.3% | 6 |
| May 2026 | Pepto-Bismol | 301K | 31.1% | 1 |
| May 2026 | Pepcid | 246K | 25.4% | 2 |
| May 2026 | Prilosec OTC | 135K | 13.9% | 3 |
| May 2026 | Tums | 135K | 13.9% | 4 |
| May 2026 | Nexium | 90.5K | 9.3% | 5 |
| May 2026 | Gaviscon | 60.5K | 6.3% | 6 |
| Jun 2026 | Pepcid | 246K | 26.9% | 1 |
| Jun 2026 | Pepto-Bismol | 246K | 26.9% | 2 |
| Jun 2026 | Prilosec OTC | 135K | 14.8% | 3 |
| Jun 2026 | Tums | 135K | 14.8% | 4 |
| Jun 2026 | Nexium | 90.5K | 9.9% | 5 |
| Jun 2026 | Gaviscon | 60.5K | 6.6% | 6 |
| Jul 2026 | Pepto-Bismol | 301K | 31.6% | 1 |
| Jul 2026 | Pepcid | 246K | 25.9% | 2 |
| Jul 2026 | Prilosec OTC | 135K | 14.2% | 3 |
| Jul 2026 | Tums | 135K | 14.2% | 4 |
| Jul 2026 | Nexium | 74K | 7.8% | 5 |
| Jul 2026 | Gaviscon | 60.5K | 6.4% | 6 |
| Aug 2026 | Pepto-Bismol | 301K | 31.1% | 1 |
| Aug 2026 | Pepcid | 246K | 25.4% | 2 |
| Aug 2026 | Prilosec OTC | 135K | 13.9% | 3 |
| Aug 2026 | Tums | 135K | 13.9% | 4 |
| Aug 2026 | Nexium | 90.5K | 9.3% | 5 |
| Aug 2026 | Gaviscon | 60.5K | 6.3% | 6 |
| Sep 2026 | Pepto-Bismol | 301K | 31.1% | 1 |
| Sep 2026 | Pepcid | 246K | 25.4% | 2 |
| Sep 2026 | Prilosec OTC | 135K | 13.9% | 3 |
| Sep 2026 | Tums | 135K | 13.9% | 4 |
| Sep 2026 | Nexium | 90.5K | 9.3% | 5 |
| Sep 2026 | Gaviscon | 60.5K | 6.3% | 6 |

## What is being compared

- **Gaviscon**: Measured on the search term “gaviscon”.
- **Nexium**: Measured on the search term “nexium”.
- **Pepcid**: Measured on the search term “pepcid”.
- **Pepto-Bismol**: Measured on the search term “pepto bismol”.
- **Prilosec OTC**: Measured on the search term “prilosec”.
- **Tums**: Measured on the search term “tums”.

- [Gaviscon](/demand/us/brands/gaviscon)
- [Nexium](/demand/us/brands/nexium)
- [Pepcid](/demand/us/brands/pepcid)
- [Pepto-Bismol](/demand/us/brands/pepto-bismol)
- [Prilosec OTC](/demand/us/brands/prilosec)
- [Tums](/demand/us/brands/tums)

## Methodology

- [How is the Brand Demand Index measured?](/demand/methodology): Where the figures come from, what they compare, and how they may be reused.

## Frequently asked questions

### Which brand is most popular in search among heartburn and digestive brands in the United States?

In September 2026, Pepto-Bismol was the most searched among heartburn and digestive brands in the United States, with an estimated 301K branded searches, 31.1% of all searches for the six we track.

## Cite this page

Brandwave. "Heartburn and digestive brands in the United States: Which are searched most?". https://gobrandwave.com/demand/us/categories/us-heartburn-and-digestive-brands

This page is also available as HTML at https://gobrandwave.com/demand/us/categories/us-heartburn-and-digestive-brands. Brandwave publishes an index of its Markdown pages at https://gobrandwave.com/llms.txt.